The US Food and Drug Administration (FDA) has approved Allergan Aesthetics’ Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe vertical platysma bands.
The approval was supported by phase III clinical studies, which showed statistically significant improvement in the appearance of platysma bands with Botox compared to placebo, successfully meeting the primary endpoint.
Allergan Aesthetics has highlighted that Botox provides a non-surgical injectable solution to enhance the appearance of neck bands and improve jawline definition, addressing a key aesthetic concern for many adults. This marks Botox’s fourth approved aesthetic indication and the first for a non-facial treatment.
Darin Messina, senior vice president at Allergan Aesthetics, an AbbVie company, commented, “Until now, treatment options have been limited and with this approval, there is a non-surgical, injectable option to temporarily improve the look of vertical bands connecting the jaw and neck. This fourth indication for Botox Cosmetic represents true innovation. We’re excited to open new doors for patients and providers, helping them to achieve their aesthetic goals.”
